다발성 골수종에서 일차치료제로서의 Cyclophosphamide와 Prednisone의 효능

Abstract

(Background) Although melphalan-based regimens are associated with numerous complications, it is usually used as front-line treatment for patients who are not indicated of autologous hematopoietic stem cell transplantation. However, another alkylating agent, cyclophosphamide, has less reports of complications. Therefore, cyclophosphamide-based regimens are usually used as a salvage therapy in patients with refractory or relapsed multiple myeloma. The purpose of this study was to evaluate the efficacy and tolerability of cyclophosphamide and prednisone (CP) as a first-line therapy for multiple myeloma (MM).

(Method) From January 2001 to March 2010, We are retrospectively analysis of 28 patients with newly multiple myeloma who received a treatment regimen that consisted of intravenous cyclophosphamide 1000mg/kg for 1 day and prednisone 100mg for 4 days.

(Result) The median progression-free survival (PFS) was 41.5 weeks. The median overall survival(OS) was 115 weeks. This combination was well tolerated. Above the grade III side effect; reduced total neutrophil count was 32.1%, reduced absolute neutrophil count (ANC) was 35.7%, reduced hemoglobin (Hb) was 57.1%, reduced platelet was 14.2% and reduced AST was 3.6%. No one developed MDS.

(Conclusion) This Combination may represent effective and well-tolerated first therapy for MM.